Sector

Healthcare

Region

AUM

12.73M

Fund Score

Range Cancer Therapeutics ETF (NASDAQ:CNCR) Quotes, Forecast and News Summary

Range Cancer Therapeutics ETF (NASDAQ: CNCR) stock price, news, charts, stock research, profile.

Open	$13.20
High	$13.51
52 Wk High	$17.96
AUM	12.73M
Dividend	-
Ex-Div Date	-
Volume	1.8K
Market Cap	$8.61B
Mgmt Fee	0.79%
P/E Ratio	31.16
Prev. Close	$13.35
Low	$13.20
52 Wk Low	$10.30
Shares Out	1.18M
Yield	-
Div. Freq	-
Avg. Volume Daily	6.48K
Beta	0.90
Avg. Expense Ratio	0.79%
P/B Ratio	1.99

Recent News

3 Top-Ranked ETFs Under $20 for Your Portfolio

Most investors want to put their money in equities but may not be able to afford large stakes in valuable companies with higher-priced stocks. For them, low-priced stocks could be attractive as these will enable them to buy more shares instead of just a handful of higher-priced shares for the same amount.

Zacks

3 ETFs For More Moderna Bets

Shares of biotechnology company Moderna Inc (NASDAQ: MRNA) jumped 20% Monday on news that its mRNA-1273 coronavirus vaccine candidate is making positive progress.

ETF Professor

Hone In On Health Care In China With This New ETF

ETF Professor

FAQ

How do I buy Range Cancer Therapeutics ETF (CNCR) stock?

You can purchase shares of Range Cancer Therapeutics ETF (NASDAQ:CNCR) through any online brokerage.

View our list of the best stock brokerages

Who are Range Cancer Therapeutics ETF (CNCR) competitors?

There are no as such competitors for Range Cancer Therapeutics ETF.

What is the forecast, or price target, for Range Cancer Therapeutics ETF (CNCR) stock?

There is no analysis for Range Cancer Therapeutics ETF to provide a consensus price target.

What is the current price for Range Cancer Therapeutics ETF (CNCR)?

The stock price for Range Cancer Therapeutics ETF (NASDAQ: CNCR) is $14 last updated November 4, 2024 at 8:52 AM EST.

Does Range Cancer Therapeutics ETF (CNCR) pay a dividend?

A quarterly cash dividend of 0.35 per share of Class A Common Stock. The quarterly cash dividend was payable on January 2, 2018 to stockholders of record on December 28, 2017.

When is Range Cancer Therapeutics ETF (NASDAQ:CNCR) reporting earnings?

Range Cancer Therapeutics ETF does not have any upcoming earnings scheduled.

Is Range Cancer Therapeutics ETF (CNCR) going to split?

There is no upcoming split for Range Cancer Therapeutics ETF.

Open	$13.20
High	$13.51
52 Wk High	$17.96
AUM	12.73M
Dividend	-
Ex-Div Date	-
Volume	1.8K
Market Cap	$8.61B
Mgmt Fee	0.79%
P/E Ratio	31.16
Prev. Close	$13.35
Low	$13.20
52 Wk Low	$10.30
Shares Out	1.18M
Yield	-
Div. Freq	-
Avg. Volume Daily	6.48K
Beta	0.90
Avg. Expense Ratio	0.79%
P/B Ratio	1.99

ETF Details

Sector	Healthcare
Category	Mid Performer-Mid Growth
Investment Style	Small Cap Blend
Fund Inception	Oct 13, 2015
Managers	Brian Cooper Gabriel Tan Todd Alberico Andrew Serowik
Definition	Most of the stocks in this Equity Fund have average financial performance and average growth potential

Investment Policy

The Fund uses a passive management (or indexing) approach to track the performance, before fees and expenses, of the Index. The Fund attempts to invest all, or substantially all, of its assets in the component securities that make up the Index. Under normal circumstances, at least 80 percent of the Funds total assets (exclusive of any collateral held from securities lending) will be invested in the component securities of the Index. Exchange Traded Concepts, LLC (ETC or the Adviser), the Funds investment adviser, expects that, over time, the correlation between the Funds performance and that of the Index, before fees and expenses, will be 95 percent or better.

Top ETF Holdings

Symbol	Name	Share %
JANX	Janux Therapeutics Inc...	4.17%
MGNX	Macrogenics Inc	3.27%
MRSN	Mersana Therapeutics I...	3.26%
YMAB	Y-Mabs Therapeutics In...	2.85%
FATE	Fate Therapeutics Inc	2.74%
IOVA	Iovance Biotherapeutic...	2.57%
AMAM	Ambrx Inc	2.54%
IBRX	Immunitybio Inc.	2.24%
SMMT	Summit Therapeutics Pl...	2.07%
RVMD	Revolution Medicines I...	2.02%

Comments

Range Cancer Therapeutics ETF

Overview